Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Titel:
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Auteur:
Moreau, Philippe Hulin, Cyrille Perrot, Aurore Arnulf, Bertrand Belhadj, Karim Benboubker, Lotfi Zweegman, Sonja Caillon, Hélène Caillot, Denis Avet-Loiseau, Hervé Delforge, Michel Dejoie, Thomas Facon, Thierry Sonntag, Cécile Fontan, Jean Mohty, Mohamad Jie, Kon-Siong Karlin, Lionel Kuhnowski, Frédérique Lambert, Jérôme Leleu, Xavier Macro, Margaret Orsini-Piocelle, Frédérique Roussel, Murielle Schiano de Colella, Jean Marc van de Donk, Niels WCJ Wuillème, Soraya Broijl, Annemiek Touzeau, Cyrille Tiab, Mourad Marolleau, Jean-Pierre Meuleman, Nathalie Vekemans, Marie-Christiane Westerman, Matthijs Klein, Saskia K Levin, Mark-David Offner, Fritz Escoffre-Barbe, Martine Eveillard, Jean-Richard Garidi, Réda Hua, Winnie Wang, Jianping Tuozzo, Alba de Boer, Carla Rowe, Melissa Vanquickelberghe, Veronique Carson, Robin Vermeulen, Jessica Corre, Jill Sonneveld, Pieter